Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kharitonov, S A
Right arrow Articles by Barnes, P J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kharitonov, S A
Right arrow Articles by Barnes, P J
Thorax 2002;57:889-896
© 2002 Thorax


ORIGINAL ARTICLE

Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma

S A Kharitonov, L E Donnelly, P Montuschi, M Corradi, J V Collins, P J Barnes

Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Royal Brompton & Harefield NHS Trust, London SW3 6LY, UK

Correspondence to:
Correspondence to:
Professor P J Barnes, Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY;
p.j.barnes{at}ic.ac.uk

Background: Dose dependent anti-inflammatory effects of inhaled corticosteroids in asthma are difficult to demonstrate in clinical practice. The anti-inflammatory effect of low dose inhaled budesonide on non-invasive exhaled markers of inflammation and oxidative stress were assessed in patients with mild asthma.

Methods: 28 patients entered a double blind, placebo controlled, parallel group study and were randomly given either 100 or 400 µg budesonide or placebo once daily, inhaled from a dry powder inhaler (Turbohaler), for 3 weeks followed by 1 week without treatment. Exhaled nitric oxide (NO), exhaled carbon monoxide (CO), nitrite/nitrate, S-nitrosothiols, and 8-isoprostanes in exhaled breath condensate were measured four times during weeks 1 and 4, and once a week during weeks 2 and 3.

Results: A dose-dependent speed of onset and cessation of action of budesonide was seen on exhaled NO and asthma symptoms. Treatment with 400 µg/day reduced exhaled NO faster (–2.06 (0.37) ppb/day) than 100 µg/day (–0.51 (0.35) ppb/day; p<0.01). The mean difference between the effect of 100 and 400 µg budesonide was –1.55 ppb/day (95% CI –2.50 to –0.60). Pretreatment NO levels were positively related to the subsequent speed of reduction during the first 3–5 days of treatment. Faster recovery of exhaled NO was seen after stopping treatment with budesonide 400 µg/day (1.89 (1.43) ppb/day) than 100 µg/day (0.49 (0.34) ppb/day, p<0.01). The mean difference between the effect of 100 and 400 µg budesonide was 1.40 ppb/day (95% CI –0.49 to 2.31). Symptom improvement was dose-dependent, although symptoms returned faster in patients treated with 400 µg/day. A significant reduction in exhaled nitrite/nitrate and S-nitrosothiols after budesonide treatment was not dose-dependent. There were no significant changes in exhaled CO or 8-isoprostanes in breath condensate.

Conclusion: Measurement of exhaled NO levels can indicate a dose-dependent onset and cessation of anti-inflammatory action of inhaled corticosteroids in patients with mild asthma.


Keywords: exhaled nitric oxide; asthma; budesonide




This article has been cited by other articles:


Home page
ChestHome page
M.-J. Oh, J.-Y. Lee, B.-J. Lee, and D.-C. Choi
Exhaled Nitric Oxide Measurement Is Useful for the Exclusion of Nonasthmatic Eosinophilic Bronchitis in Patients With Chronic Cough
Chest, November 1, 2008; 134(5): 990 - 995.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
Z. L. Borrill, K. Roy, and D. Singh
Exhaled breath condensate biomarkers in COPD
Eur. Respir. J., August 1, 2008; 32(2): 472 - 486.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
I. H. van Veen, A. ten Brinke, P. J. Sterk, J. K. Sont, S. A. Gauw, K. F. Rabe, and E. H. Bel
Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma
Eur. Respir. J., August 1, 2008; 32(2): 344 - 349.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. G. Lim and C. Mottram
The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice
Chest, May 1, 2008; 133(5): 1232 - 1242.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Respir DisHome page
P. Montuschi
Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications
Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 5 - 23.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. Travers, S. Marsh, S. Aldington, M. Williams, P. Shirtcliffe, A. Pritchard, M. Weatherall, and R. Beasley
Reference Ranges for Exhaled Nitric Oxide Derived from a Random Community Survey of Adults
Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 238 - 242.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K. Roy, Z. L. Borrill, C. Starkey, A. L. Hazel, J. Morris, J. Vestbo, and D. Singh
Use of different exhaled nitric oxide multiple flow rate models in COPD
Eur. Respir. J., April 1, 2007; 29(4): 651 - 659.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. Paredi, S. Ward, D. Cramer, P. J. Barnes, and S. A. Kharitonov
Normal Bronchial Blood Flow in COPD Is Unaffected by Inhaled Corticosteroids and Correlates With Exhaled Nitric Oxide
Chest, April 1, 2007; 131(4): 1075 - 1081.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. J. Barnes
Scientific rationale for using a single inhaler for asthma control
Eur. Respir. J., March 1, 2007; 29(3): 587 - 595.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J. Batra, T. Pratap Singh, U. Mabalirajan, A. Sinha, R. Prasad, and B. Ghosh
Association of inducible nitric oxide synthase with asthma severity, total serum immunoglobulin E and blood eosinophil levels
Thorax, January 1, 2007; 62(1): 16 - 22.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. A. Kharitonov and P. J. Barnes
Exhaled biomarkers.
Chest, November 1, 2006; 130(5): 1541 - 1546.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
T. Haahtela, K. Tamminen, L. P. Malmberg, O. Zetterstrom, J. Karjalainen, H. Yla-Outinen, T. Svahn, T. Ekstrom, and O. Selroos
Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study
Eur. Respir. J., October 1, 2006; 28(4): 748 - 755.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste
Exhaled nitric oxide measurements: clinical application and interpretation
Thorax, September 1, 2006; 61(9): 817 - 827.
[Abstract] [Full Text] [PDF]


Home page
Biol Res NursHome page
J. Choi, L. A. Hoffman, G. W. Rodway, and J. M. Sethi
Markers of lung disease in exhaled breath: nitric oxide.
Biol Res Nurs, April 1, 2006; 7(4): 241 - 255.
[Abstract] [PDF]


Home page
Eur Respir JHome page
I. Horvath, J. Hunt, P. J. Barnes, and On behalf of the ATS/ERS Task Force on Exhaled Bre
Exhaled breath condensate: methodological recommendations and unresolved questions
Eur. Respir. J., September 1, 2005; 26(3): 523 - 548.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. E. Overbeek, P. G. Mulder, S. M. Baelemans, H. C. Hoogsteden, and J.-B. Prins
Formoterol Added to Low-Dose Budesonide Has No Additional Antiinflammatory Effect in Asthmatic Patients
Chest, September 1, 2005; 128(3): 1121 - 1127.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. D. Smith, J. O. Cowan, K. P. Brassett, S. Filsell, C. McLachlan, G. Monti-Sheehan, G. P. Herbison, and D. R. Taylor
Exhaled Nitric Oxide: A Predictor of Steroid Response
Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 453 - 459.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S Battaglia, H den Hertog, M C Timmers, S P G Lazeroms, A M Vignola, K F Rabe, V Bellia, P S Hiemstra, and P J Sterk
Small airways function and molecular markers in exhaled air in mild asthma
Thorax, August 1, 2005; 60(8): 639 - 644.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. D. Smith, J. O. Cowan, K. P. Brassett, G. P. Herbison, and D. R. Taylor
Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma
N. Engl. J. Med., May 26, 2005; 352(21): 2163 - 2173.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Baydur
Not All That Comes Out Is Hot Air
Chest, May 1, 2005; 127(5): 1482 - 1485.
[Full Text] [PDF]


Home page
ThoraxHome page
I Horvath
The exhaled biomarker puzzle: bacteria play their card in the exhaled nitric oxide-exhaled breath condensate nitrite game
Thorax, March 1, 2005; 60(3): 179 - 180.
[Full Text] [PDF]


Home page
ThoraxHome page
G E Carpagnano, S A Kharitonov, M P Foschino-Barbaro, O Resta, E Gramiccioni, and P J Barnes
Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation
Thorax, December 1, 2004; 59(12): 1016 - 1019.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
S. A. Kharitonov and P. J. Barnes
Effects of Corticosteroids on Noninvasive Biomarkers of Inflammation in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 191 - 199.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S.A. Kharitonov, F. Gonio, C. Kelly, S. Meah, and P.J. Barnes
Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children
Eur. Respir. J., March 1, 2003; 21(3): 433 - 438.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 BMJ Publishing Group Ltd & British Thoracic Society